Members of the Office of Health Economics (OHE) recently attended and presented key research at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad. Summaries of their presentations are available here. (Source: Office of Health Economics, 6/19/15) […]
Check Out the New Issue of ISPOR’s Value in Health
The June 2015 issue of Value in Health, the journal of the International Society for Pharmacoeconomics and Outcomes Research is now available to view online! Don't miss the Featured article assessing the quality of the clinical evidence in submissions to the Australian Pharmaceutical Benefits […]
Is the U.S. Pharmaceutical Market Living in a Bubble?
Pharma and biotechs dealing mostly in the U.S. may think they've seen they worst of market encroachment, but that may not be true, according to Michael Abrams, managing partner at the health care consulting firm Numerof & Associates. Read more here. (Source: Marie Powers, BioWorld) […]
Do You Speak My Language? When Patient Care Meets Cost-Effectiveness
Health system innovations are sometimes justified in economic language, but clinicians speak the language of patient care. Advancing reform requires translators who speak both languages. Read more here. (Source: AJMC, 6,12,15) […]
How do Policymakers View and Use CER?
Joel Weissman and colleagues recently had a study published in the Journal of Comparative Effectiveness Research. Their overarching question: How do senior coverage policymakers view and use CER? Find out what they learned and more here. (Source: AcademyHealth Blog, 6/15/15) […]
How Does the 21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety?
Jim Davis, Executive Vice President of Adverse Events recently wrote a blog for tHEORetically Speaking on the benefits of the 21st Century Cures and Off-Label Promotion to HEOR and Drug Safety. Read more here. (Source: Jim Davis, tHEORetically Speaking, 6/4/15) […]
Will Oncologists’ Push for Cost-Effectiveness Help Lower Pricing?
The American Society of Clinical Oncology recently held its annual conference in Chicago where pharmaceutical companies touted new cancer therapies and potential breakthroughs, however many speakers were focused on the skyrocketing costs of cancer drugs, calling for the explicit consideration of […]
ICER on Integrating Behavioral Health into Primary Care
The Institute for Clinical and Economic Review (ICER) recently posted the final report Integrating Behavioral Health into Primary Care and its accompanying action guides and policy brief to the CTAF and CEPAC websites. More information available here. (Source: ICER, 6/2/15) […]
CEPAC Names New Members for 2015
The Institute for Clinical and Economic Review (ICER) has announced the new members of the 2015 New England Comparative Effectiveness Public Advisory Council (CEPAC). Meet the council members here. (Source: ICER, 4/24/15) […]
OHE Publishes in the Journal of Comparative Effectiveness Research
The Journal of Comparative Effectiveness Research recently published a series of three articles exploring future expectation for new drugs of evidence. of relative effectiveness in Europe and comparative effectiveness in the USA in 2020. Available online and free to download, see more here. (Source: […]
Why is CER Taking So Long to Impact Healthcare Decision Making
The purpose of Comparative Effectiveness Research (CER) was to provide healthcare decision makers with better information about treatment alternatives, but so far, CER has not made much of an impact. How long will it take for CER's impact to be seen in healthcare? Read more here. (Source: Laura […]
PCORI Shown as a National Leader in CER
The National Pharmaceutical Council (NPC) recently discussed the results of its fifth annual healthcare stakeholder survey. The survey found clear enthusiasm for Clinical Effectiveness Research (CER) as a means of improving health and health care. The survey also found PCORI to be the predominant […]
Why Must Oncologists Remain Wary of Non-Inferiority Trials?
Sometimes erroneously thought of as equivalence trials, non-inferiority trials do not show superiority of the test drug, but show the new treatment is not inferior to an unacceptable extent. Read more here. (Source: Mauricio Burotto, Vinay Prasad, Tito Fojo, The Lancet Oncology, […]
National Pharmaceutical Council. 2014 Comparative Effectiveness Research and Environment Health Care Decision-Making Infographic.
Or download the infographic PDF file here. […]
NPCs Infographic On Comparative Effectiveness Research
The National Pharmaceutical Council's fourth annual survey of health care stakeholders sheds some light on the environment for comparative effectiveness research (CER) and health care decision-making. How important is CER? Which organizations play key roles in the CER effort? How long will it take […]
How Do We Decide Which Drug Is Best?
Whenever possible, we need publicly funded trials for comparative effectiveness research, designed to evaluate similar drugs at comparable doses to determine their real comparative safety and efficacy. How else do we answer the question, "Is it really better?" Read more here. (Source: Robert Bohrer, […]
Fifth Annual Survey On CER & Health Care Decision-Making
Read this Q&A with the National Pharmaceutical Pharmacy"s Kimberly Westrich, vice president of health services research, as she speaks about the Fifth Annual Survey On CER & Healthcare Decision-Making: What Can We Expect This Year? Through this annual survey, the National Pharmaceutical […]
How Can Real World Data Be Used To Develop And Use Medicines?
A focus on the facilitation of greater openness among public and private stakeholders to collaboration, connecting information and data sharing, with the goal of making robust and complete data accessible to all researchers. See this issue of Value In Health here. (Source: Value in Health 18) […]
Obamacare To Fund Hep C Comparative-Effectiveness Research
According to a recent release from the Patient-Centered Outcomes Research Institute, Obamacare's comparative-effectiveness research panel has offered $50 million to compare diagnostics and drugs for Hepatitis C. Learn more here. (Source: InsideHealthPolicy, 2/9/15) […]
Biopharma Products Not ‘On Radar’ For Medicare Coverage Review
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions. Available for purchase here. […]
Are You Familiar With PCORI’s Principles Of Collaboration?
PCORI has established a number of valuable partnerships. To ensure that these joint efforts run effectively, transparently, and produce high-quality research, the Board of Governors has approved the PCORI Collaboration Principles. See more here. (Source: pcori, 12/8/14). […]
PCORI – What’s Next For Hepatitis C Research?
If approved, the PCORI Funding Announcement (PFA) would commit up to $50 million in research funding and seek proposals to address CER questions. Learn more here. (Source: PCORI, 12/5/14). […]
Early Access & Adaptive Licensing – Hot Topics At ISPOR Europe Annual Meeting
Given the high amount of interest in early access by the pharmaceutical companies, payers and patients, it isn't surprising to see how much of a focus it was at the recent ISPOR 17th Annual European Congress. See more on what was talked about, here. (Source: Milena Izmirlieva, iHS, 12/3/14). […]
Why Is Observational CER Gaining Popularity In China?
Observational Comparative Effectiveness Research's lower cost and greater efficiency, compared to RCTs, has led to a substantial interest in China. Read more about China's increased use of Observation CER and why it's gaining popularity now, here. (Source: PharmaAsia, 11/01/14). […]
Check Out The Newest THETA Rounds Lecture For A Brief History Of The Health Utilities Index
THETA has been hosting a lecture series THETA Rounds since 2008 and inviting world experts to address various issues related to the Health Technology Assessment field. The newest recorded lecture, A Brief History of the Health Utilities Index (HUI). David Feeny, PhD, can be found here. (Source: […]
What Is Your Opinion On Informed Consent Rules In Comparison Studies – We Want To Know!
The federal government is considering possible changes to what risks and benefits researchers must describe to patients who participate in studies comparing the effectiveness of already approved treatments and procedures. But, researchers say the new process would confuse researchers and mislead […]
New Draft Guidelines Involving Risks In Comparative-Effectiveness Research – A Confusing Clarification
New draft guidelines recently issued by the federal Office for Human Research Protections (OHRP) regarding the evaluation and disclosure of risks in comparative-effectiveness research (CER) fail to clarify current federal policy. If adopted, the result of this approach will be consent forms that […]
New Journal Targets Real-World Data, Health Outcomes, Healthcare Decision-Making & Big Data
Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs-Real World Outcomes has a broad scope, encompassing studies investigating drug […]
How Do You Decide The Relevance And Credibility Of Observational Studies?
Four Good Practices task forces developed consensus-based questionnaires to help decision makers evaluate: 1) prospective and 2) retrospective observational studies, 3) network meta-analysis, and 4) decision analytic modeling studies with greater uniformity and transparency. Based on feedback from […]
How Does Crossover Affect Overall Survival Analysis In Randomized Controlled Trials
During oncology clinical trials, if a patient's disease progresses, they are often given the opportunity to cross over to active treatment. This alleviates ethical issues associated with placebo controls, but how does it effect the analysis of overall survival and cost-effectiveness? Read more here. […]
